DocMorris reported 2025 external revenue of CHF 1.19 billion, an 11.1% increase from the prior year. The Dutch online pharmacy saw a strong finish, with fourth-quarter external revenue rising 15.5% in local currency. This acceleration followed the 2024 discontinuation of its Zur Rose brand in Germany, marking a pivotal turnaround for the company.

Growth was powered by Germany, its largest market, where prescription drug sales surged 33.2% for the full year. Non-prescription products also climbed 7.1%. The standout performer was digital services, which more than doubled revenue. TeleClinic jumped 124% and retail media services rose 88%, highlighting a successful shift toward higher-margin digital offerings.

DocMorris confirmed its 2025 EBITDA loss guidance but reiterated targets for EBITDA breakeven in 2026 and free cash flow breakeven in 2027. The company's active customer base grew to 11 million. Investors will watch if digital momentum can offset legacy pharmacy challenges and sustain the path to profitability.